RGNX
Regenxbio Inc

2,554
Mkt Cap
$680.88M
Volume
906,733.00
52W High
$13.93
52W Low
$5.04
PE Ratio
-3.80
RGNX Fundamentals
Price
$13.20
Prev Close
$13.45
Open
$13.53
50D MA
$11.38
Beta
1.62
Avg. Volume
608,908.61
EPS (Annual)
-$4.59
P/B
4.16
Rev/Employee
$236,056.66
Loading...
Loading...
News
all
press releases
REGENXBIO (NASDAQ:RGNX) Trading Up 10.7% After Analyst Upgrade
REGENXBIO (NASDAQ:RGNX) Trading 10.7% Higher Following Analyst Upgrade...
MarketBeat·9h ago
News Placeholder
More News
News Placeholder
Brokers Set Expectations for REGENXBIO FY2026 Earnings
REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities researchers at Chardan Capital cut their FY2026 earnings estimates for shares of REGENXBIO in a research note issued to investors on Thursday...
MarketBeat·3d ago
News Placeholder
REGENXBIO (NASDAQ:RGNX) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research note on Monday...
MarketBeat·3d ago
News Placeholder
Savant Capital LLC Invests $226,000 in REGENXBIO Inc. $RGNX
Savant Capital LLC purchased a new position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm...
MarketBeat·7d ago
News Placeholder
REGENXBIO (NASDAQ:RGNX) Cut to "Sell" at Wall Street Zen
Wall Street Zen cut shares of REGENXBIO from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·11d ago
News Placeholder
Los Angeles Capital Management LLC Makes New Investment in REGENXBIO Inc. $RGNX
Los Angeles Capital Management LLC bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and...
MarketBeat·13d ago
News Placeholder
REGENXBIO (NASDAQ:RGNX) Posts Earnings Results, Beats Expectations By $0.18 EPS
REGENXBIO (NASDAQ:RGNX - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($1.20) EPS for the quarter, beating analysts' consensus estimates of...
MarketBeat·18d ago
News Placeholder
REGENXBIO (NASDAQ:RGNX) Price Target Raised to $19.00
Royal Bank Of Canada upped their price target on REGENXBIO from $17.00 to $19.00 and gave the stock an "outperform" rating in a report on Friday...
MarketBeat·18d ago
News Placeholder
Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of +13.04% and +23.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21d ago
News Placeholder
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial...
PR Newswire·28d ago

Latest RGNX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.